New biomarker may predict who benefits from AS therapy: Study
A heightened type 1 interferon (IFN) immune response and elevated levels of AIF-1 protein may help identify ankylosing spondylitis (AS) patients at risk of not improving from treatment with tumor necrosis factor inhibitors (TNFi), a study shows. The study also defined a cutoff value of AIF-1 that could make…